Rani Therapeutics Holdings, Inc. (RANI)

USD 1.08

(0.93%)

Market Cap (In USD)

62.14 Million

Revenue (In USD)

-

Net Income (In USD)

-33.97 Million

Avg. Volume

838.25 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.33-8.75
PE
-1.03
EPS
-1.05
Beta Value
0.114
ISIN
US7530181004
CUSIP
753018100
CIK
1856725
Shares
57542256.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Talat Imran
Employee Count
-
Website
https://www.ranitherapeutics.com
Ipo Date
2021-07-30
Details
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.